Ainos, INC 8-K filings

Ainos, Inc. announced its first quarter 2024 financial results, highlighting a strategic shift away from COVID-19 rapid tests and securing $9 million in growth capital.

Ainos Inc. has entered into a convertible note and warrant purchase agreement with ASE Test, Inc., securing a $9 million investment and a voting agreement.

Ainos, Inc. has appointed Christopher Hsin-Liang Lee as its new Chief Financial Officer, effective March 18, 2024.

Ainos Inc. reports the resignation of its Chief Financial Officer, Meng-Lin Sung, effective March 13, 2024.

Ainos Inc. announced its full year 2023 financial results, highlighting a strategic pivot towards VELDONA and AI-powered point-of-care testing, despite a significant revenue decrease due to reduced COVID-19 test kit sales.

Ainos, Inc. has submitted a complete response to the FDA to resolve a clinical hold on its Phase 2 trial of VELDONA for mild COVID-19.

Ainos, Inc. has secured an additional $1.75 million in funding through an amendment to its existing convertible promissory note with Lind Global Fund II L.P., extending the maturity date and adjusting other terms.

Ainos Inc. has entered into an addendum to its existing product development agreement with Taiwan Carbon Nano Technology Corporation, outlining new co-development projects and associated costs.